Talphera (TLPH) Research & Development (2010 - 2026)
Talphera's (TLPH) quarterly Research & Development came in at $1.6 million in Q1 2026, up 41.15% year-on-year from $1.2 million in Q1 2025, and up 5.7% quarter-over-quarter from $1.6 million in Q4 2025.
Talphera (TLPH) Research & Development (2010 - 2026) Analysis & Trends
Talphera's Research & Development history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- On a quarterly basis, Research & Development rose 41.15% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $6.5 million, a 0.93% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, down 10.2% from the prior year.
- Research & Development rose to $1.6 million in Q1 2026 per TLPH's latest filing, from $1.6 million in the prior quarter.
- Across five years, Research & Development topped out at $2.1 million in Q3 2024 and bottomed at $612000.0 in Q4 2022.
- The 5-year median for Research & Development is $1.5 million (2024), against an average of $1.4 million.
- Across the five-year window, Research & Development tumbled 43.57% in 2022 and jumped 189.05% in 2023, its largest moves.
- Year by year, Research & Development stood at $612000.0 in 2022, then soared by 189.05% to $1.8 million in 2023, then dropped by 25.21% to $1.3 million in 2024, then rose by 17.99% to $1.6 million in 2025, then advanced by 5.7% to $1.6 million in 2026.
- Per Business Quant, the three latest TLPH Research & Development figures stand at $1.6 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 138.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Talphera | 94.61 Mn | 56.78 Mn | - | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.50 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 1.91 Mn |
| Mar 31, 2024 | 1.43 Mn |
| Dec 31, 2023 | 1.77 Mn |
| Sep 30, 2023 | 1.18 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 612,000.00 |
| Sep 30, 2022 | 799,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.32 Mn |
| Dec 31, 2021 | 986,000.00 |
| Sep 30, 2021 | 1.42 Mn |
| Jun 30, 2021 | 724,000.00 |
| Mar 31, 2021 | 969,000.00 |